FORM 2

THE PATENTS ACT, 1970
(39 of 1970)
AND
THE PATENTS RULES, 2003

COMPLETE SPECIFICATION

(See Section 10; rule 13)

TITLE OF THE INVENTION

"(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS"

APPLICANT

Oryzon Genomics, S.A.
of C/Sant Ferran, 74, E-08940, Cornellà De Llobregat, Spain; Nationality: Spain

The following specification particularly describes
the invention and the manner in which
it is to be performed

CLAIMS

1. A compound of Formula I



I

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and -C_{1-4} alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and

each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol,
2-((2-phenylcyclopropyl)amino)cyclopentanol, and
2-((2-phenylcyclopropyl)amino)cyclohexanol.

2. A compound of Formula I



I

wherein:
A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl; and

the substituents –A-B and –NH-D on the cyclopropyl moiety are in trans-configuration;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol.

3. A compound of Formula I



I

wherein:
A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group $-(C(R^a)_2)_p-$ linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S,

wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl; and

the compound is an optically active stereoisomer;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol.

4. A compound of formula I



I

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from –NR^7R^8, -NHOH, -NR^9COR^{10}, -$NR^9SO_2R^{10}$, -NR^9COOR^{10}, -$NR^9CONR^7R^8$, -$NR^9SO_2NR^7R^8$, -OH, –$CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and –C_{1-4} alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and

each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol;

for use as a medicament.

5. The compound for use as a medicament according to claim 4, wherein said compound is a compound of formula Ia

Ia

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from –NR^7R^8, -NHOH, -NR^9COR^{10}, -$NR^9SO_2R^{10}$, -NR^9COOR^{10}, -$NR^9CONR^7R^8$, -$NR^9SO_2NR^7R^8$, -OH, –$CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-

NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and –C_{1-4} alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and –$NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl; and

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol.

6. The compound of any of claims 1 to 3 for use as a medicament.

7. A pharmaceutical composition comprising a compound of formula I



I

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and

each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol,

and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7, wherein said compound is a compound of formula Ia

Ia

wherein:
A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl; and

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol.

9. A pharmaceutical composition comprising the compound of any of claims 1 to 3 and a pharmaceutically acceptable carrier.

10. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is selected from D1, D2, D3 and D4:



D1 D2 D3 D4

wherein the cyclobutyl ring comprised in D1, the cyclopentyl ring comprised in D2, the cyclohexyl ring comprised in D3 and the cycloheptyl ring comprised in D4 is optionally substituted with one further R^3 and is optionally substituted with one or more R^4; wherein the cyclobutyl ring comprised in D1 optionally:

(a) is bonded to a linker group $-(C(R^a)_2)_p-$ linking together any two non-adjacent ring carbon atoms of the cyclobutyl ring, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(b) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cyclobutyl ring via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

and wherein the cyclopentyl ring comprised in D2, the cyclohexyl ring comprised in D3 and the cycloheptyl ring comprised in D4 optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group $-(C(R^a)_2)_p-$ linking together any two non-adjacent ring carbon atoms of the cyclopentyl ring comprised in D2, the cyclohexyl ring comprised in D3 or the cycloheptyl ring comprised in D4, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cyclopentyl ring comprised in D2, the cyclohexyl ring comprised in D3 or the cycloheptyl ring comprised in D4 via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6.

11. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is selected from D1, D2, D3 and D4:



D1 D2 D3 D4

wherein the cyclobutyl ring comprised in D1, the cyclopentyl ring comprised in D2, the cyclohexyl ring comprised in D3 and the cycloheptyl ring comprised in D4 is optionally substituted with one or more R^4.

12. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



wherein the cyclohexyl ring comprised in D is optionally substituted with one further R^3 and is optionally substituted with one or more R^4, and wherein the cyclohexyl ring comprised in D optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group $-(C(R^a)_2)_p-$ linking together any two non-adjacent ring carbon atoms of the cyclohexyl ring, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cyclohexyl ring via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6.

13. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



wherein the cyclohexyl ring comprised in D is optionally substituted with one or more R^4, and wherein the cyclohexyl ring comprised in D optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group $-(C(R^a)_2)_p-$ linking together any two non-adjacent ring carbon atoms of the cyclohexyl ring, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cyclohexyl ring via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6.

14. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



wherein the cyclohexyl ring comprised in D is optionally substituted with one or more R^4.

15. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



16. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4.

17. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one substituent R^3 and is further optionally substituted with one or more R^4.

18. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one substituent R^3.

19. The compound of any of claims 1 to 3 or 16 to 18 or the compound for use as a medicament according to any of claims 4 to 6 or 16 to 18 or the pharmaceutical composition of any of claims 7 to 9 or 16 to 18, wherein the cycloalkyl group having from 4 to 7 C atoms which forms part of D is a cyclohexyl group.

20. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



wherein the cyclobutyl ring comprised in D is optionally substituted with one or more R^4.

21. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



wherein the cyclohexyl ring comprised in D is optionally substituted with one or more R^4.

22. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, $-CONR^7R^8$, oxo, $-C_{1-4}$ alkylene-NR^7R^8, $-C_{1-4}$ alkylene-NHOH, $-C_{1-4}$ alkyene-NR^9COR^{10}, $-C_{1-4}$ alkylene-$NR^9SO_2R^{10}$, $-C_{1-4}$ alkylene-NR^9COOR^{10}, $-C_{1-4}$ alkylene-$NR^9CONR^7R^8$, $-C_{1-4}$ alkylene-$NR^9SO_2NR^7R^8$, $-C_{1-4}$ alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$.

23. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, oxo, $-C_{1-4}$ alkylene-NR^7R^8, $-C_{1-4}$ alkylene-NHOH, $-C_{1-4}$ alkyene-NR^9COR^{10}, $-C_{1-4}$ alkylene-$NR^9SO_2R^{10}$, $-C_{1-4}$ alkylene-NR^9COOR^{10}, $-C_{1-4}$ alkylene-$NR^9CONR^7R^8$, $-C_{1-4}$ alkylene-$NR^9SO_2NR^7R^8$, and $-C_{1-4}$ alkylene-OH.

24. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, and oxo.

25. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, -OH, $-CONR^7R^8$, and oxo.

26. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -OH, oxo, $-C_{1-4}$ alkylene-NR^7R^8, and $-C_{1-4}$ alkylene-OH.

27. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$ and $-C_{1-4}$ alkylene-NR^7R^8.

28. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$.

29. The compound of any of claims 1 to 3 or 10 to 28 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 28 or the pharmaceutical composition of any of claims 7 to 28, wherein R^7 and R^8 are each independently selected from hydrogen, C_{1-8} alkyl, H_2N-C_{1-8} alkyl and hydroxyC_{1-8} alkyl.

30. The compound of any of claims 1 to 3 or 10 to 28 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 28 or the pharmaceutical composition of any of claims 7 to 28, wherein R^7 and R^8 are each hydrogen.

31. The compound of any of claims 1 to 3 or 10 to 28 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 28 or the pharmaceutical composition of any of claims 7 to 28, wherein R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11}.

32. The compound of any of claims 1 to 3 or 10 to 28 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 28 or the pharmaceutical composition of any of claims 7 to 28, wherein $-NR^7R^8$ is a group of formula:



33. The compound of any of claims 1 to 3, 10, 12, 16, 19 or 22 to 32 or the compound for use as a medicament according to any of claims 4 to 6, 10, 12, 16, 19 or 22 to 32 or the pharmaceutical composition of any of claims 7 to 10, 12, 16, 19 or 22 to 32, wherein said compound comprises one group R^3.

34. The compound of any of claims 1 to 3 or 10 to 33 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 33 or the pharmaceutical composition of any of claims 7 to 33, wherein A is phenyl, naphthyl or monocyclic heteroaryl, wherein said phenyl, said naphthyl or said monocyclic heteroaryl is optionally substituted with one or more R^1.

35. The compound of any of claims 1 to 3 or 10 to 33 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 33 or the pharmaceutical composition of any of claims 7 to 33, wherein A is phenyl or monocyclic heteroaryl, wherein said phenyl or said monocyclic heteroaryl is optionally substituted with one or more R^1.

36. The compound of any of claims 1 to 3 or 10 to 33 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 33 or the pharmaceutical composition of any of claims 7 to 33, wherein A is phenyl, pyridyl, thiophenyl, pyrrolyl, furanyl, or thiazolyl, wherein said phenyl, said pyridyl, said thiophenyl, said pyrrolyl, said furanyl, or said thiazolyl is optionally substituted with one or more R^1.

37. The compound of claim 36 or the compound for use as a medicament according to claim 36 or the pharmaceutical composition of claim 36, wherein A is phenyl, pyridyl, thiazolyl, or thiophenyl, wherein said phenyl, said pyridyl, said thiazolyl or said thiophenyl is optionally substituted with one or more R^1.

38. The compound of claim 36 or the compound for use as a medicament according to claim 36 or the pharmaceutical composition of claim 36, wherein A is phenyl, pyridyl or thiazolyl, wherein said phenyl, said pyridyl or said thiazolyl is optionally substituted with one or more R^1.

39. The compound of claim 38 or the compound for use as a medicament according to claim 38 or the pharmaceutical composition of claim 38, wherein A is phenyl, 3-pyridyl or 5-thiazolyl, wherein said phenyl, said 3-pyridyl or said 5-thiazolyl is optionally substituted with one or more R^1.

40. The compound of claim 39 or the compound for use as a medicament according to claim 39 or the pharmaceutical composition of claim 39, wherein A is phenyl or 3-pyridyl, wherein said phenyl or said 3-pyridyl is optionally substituted with one or more R^1.

41. The compound of claim 40 or the compound for use as a medicament according to claim 40 or the pharmaceutical composition of claim 40, wherein A is phenyl optionally substituted with one or more R^1.

42. The compound of claim 40 or the compound for use as a medicament according to claim 40 or the pharmaceutical composition of claim 40, wherein A is 3-pyridyl optionally substituted with one or more R^1.

43. The compound of claim 39 or the compound for use as a medicament according to claim 39 or the pharmaceutical composition of claim 39, wherein A is 5-thiazolyl optionally substituted with one or more R^1.

44. The compound of claim 34 or the compound for use as a medicament according to claim 34 or the pharmaceutical composition of claim 34, wherein A is naphthyl optionally substituted with one or more R^1.

45. The compound of any of claims 1 to 3 or 10 to 44 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 44 or the pharmaceutical composition of any of claims 7 to 44, wherein B is hydrogen or R^1.

46. The compound of claim 45 or the compound for use as a medicament according to claim 45 or the pharmaceutical composition of claim 45, wherein B is hydrogen.

47. The compound of claim 46 or the compound for use as a medicament according to claim 46 or the pharmaceutical composition of claim 46, wherein A is substituted with 1 or 2 groups R^1.

48. The compound of claim 47 or the compound for use as a medicament according to claim 47 or the pharmaceutical composition of claim 47, wherein A is substituted with 1 group R^1.

49. The compound of any of claims 1 to 3 or 10 to 44 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 44 or the pharmaceutical composition of any of claims 7 to 44, wherein B is –L-E.

50. The compound of any of claims 1 to 3 or 10 to 49 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 49 or the pharmaceutical composition of any of claims 7 to 49, wherein each R^1 is independently selected from C_{1-8} alkyl, cyclyl, amino, amido, hydroxyl, halo, haloC_{1-8} alkyl, haloC_{1-8}alkoxy, cyano, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, carbamate, and urea.

51. The compound of any of claims 1 to 3 or 10 to 49 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 49 or the pharmaceutical composition of any of claims 7 to 49, wherein each R^1 is independently selected from C_{1-8} alkyl, amino, amido, hydroxyl, halo, haloC_{1-8} alkyl, haloC_{1-8}alkoxy, cyano, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, carbamate, and urea.

52. The compound of any of claims 1 to 3 or 10 to 49 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 49 or the pharmaceutical composition of any of claims 7 to 49, wherein each R^1 is independently selected from halo, C_{1-4} alkyl, haloC_{1-4} alkyl, C_{1-4} alkoxy and C_{3-6} cycloalkyl.

53. The compound of claim 46 or 49 or the compound for use as a medicament according to claim 46 or 49 or the pharmaceutical composition of claim 46 or 49, wherein A is not substituted with any R^1.

54. The compound of claim 46 or the compound for use as a medicament according to claim 46 or the pharmaceutical composition of claim 46, wherein A is not substituted with any R^1.

55. The compound of claim 49 or the compound for use as a medicament according to claim 49 or the pharmaceutical composition of claim 49, wherein A is not substituted with any R^1.

56. The compound of any of claims 1 to 3, 10 to 44, 49 to 53 or 55 or the compound for use as a medicament according to any of claims 4 to 6, 10 to 44, 49 to 53 or 55 or the pharmaceutical composition of any of claims 7 to 44, 49 to 53 or 55, wherein L is a bond, -O-, -NH-, $-CH_2-NH-$, or $-CH_2-O-$, wherein said $-CH_2-NH-$ and $-CH_2-O-$ groups are linked to ring A through the N or O atom, respectively, and are linked to ring E through the $-CH_2-$ group comprised in said $-CH_2-NH-$ and $-CH_2-O-$ groups.

57. The compound of claim 56 or the compound for use as a medicament according to claim 56 or the pharmaceutical composition of claim 56, wherein L is a bond.

58. The compound of claim 56 or the compound for use as a medicament according to claim 56 or the pharmaceutical composition of claim 56, wherein L is $-CH_2-O-$ linked to ring A through the O atom comprised in said $-CH_2-O-$ and linked to ring E through the $-CH_2-$ group comprised in said $-CH_2-O-$.

59. The compound of claim 56 or the compound for use as a medicament according to claim 56 or the pharmaceutical composition of claim 56, wherein L is -NH- or L is $-CH_2-NH-$ linked to ring A through the N atom comprised in said $-CH_2-NH-$ and linked to ring E through the $-CH_2-$ group comprised in said $-CH_2-NH-$.

60. The compound of any of claims 1 to 3, 10 to 44, 49 to 53 or 55 to 59 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 44, 49 to 53 or 55 to 59 or the pharmaceutical composition of any of claims 7 to 44, 49 to 53 or 55 to 59, wherein E is phenyl which is optionally substituted with one or more R^2.

61. The compound of claim 60 or the compound for use as a medicament according to claim 60 or the pharmaceutical composition of claim 60, wherein E is phenyl.

62. The compound of claim 60 or the compound for use as a medicament according to claim 60 or the pharmaceutical composition of claim 60, wherein E is phenyl which is substituted with one R^2.

63. The compound of any of claims 1 to 3, 10 to 44, 49 to 53 or 55 to 59 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 44, 49 to 53 or 55 to 59 or the pharmaceutical composition of any of claims 7 to 44, 49 to 53 or 55 to 59, wherein E is heteroaryl optionally substituted with one or more R^2.

64. The compound of claim 63 or the compound for use as a medicament according to claim 63 or the pharmaceutical composition of claim 63, wherein E is pyridinyl, pyrazolyl, or indazolyl.

65. The compound of claim 63 or the compound for use as a medicament according to claim 63 or the pharmaceutical composition of claim 63, wherein E is pyridinyl, pyrazolyl, or indazolyl, wherein said pyridinyl, said pyrazolyl or said indazolyl is substituted with one R^2.

66. The compound of any of claims 1 to 3, 10 to 44, 49 to 53, 55 to 60, 62, 63 or 65 or the compound for use as a medicament according to any of claims 4 to 6, 10 to 44, 49 to 53, 55 to 60, 62, 63 or 65 or the pharmaceutical composition of any of claims 7 to 44, 49 to 53, 55 to 60, 62, 63 or 65, wherein each R^2 is independently selected from C_{1-8} alkyl, hydroxyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, N-sulfonamido, and C_{1-8} alkoxy.

67. The compound of any of claims 1 to 3, 10 to 44, 49 to 53, 55 to 60, 62, 63 or 65 or the compound for use as a medicament according to any of claims 4 to 6, 10 to 44, 49 to 53, 55 to 60, 62, 63 or 65 or the pharmaceutical composition of any of claims 7 to 44, 49 to 53, 55 to 60, 62, 63 or 65, wherein each R^2 is independently selected from hydroxyl, halo, haloC_{1-8} alkyl and N-sulfonamido.

68. The compound of claim 67 or the compound for use as a medicament according to claim 67 or the pharmaceutical composition of claim 67, wherein each R^2 is independently selected from hydroxyl, halo and haloC_{1-8} alkyl.

69. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein each R^w, R^x, R^y and R^z is independently selected from hydrogen, fluoro and C_{1-4} alkyl.

70. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein each R^w, R^x, R^y and R^z is independently selected from hydrogen and fluoro.

71. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein R^w is selected from hydrogen, halo and C_{1-4} alkyl and each R^x, R^y and R^z is hydrogen.

72. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein each R^w, R^x, R^y and R^z is hydrogen.

73. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl, wherein at least one of R^w, R^x, R^y and R^z is not hydrogen.

74. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein R^w is selected from halo and C_{1-4} alkyl, and each R^x, R^y and R^z is hydrogen.

75. The compound of claim 74 or the compound for use as a medicament according to claim 74 or the pharmaceutical composition of claim 74, wherein R^w is selected from fluoro and methyl, and each R^x, R^y and R^z is hydrogen.

76. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein R^w is fluoro and each R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl.

77. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein R^z is fluoro and each R^w, R^x and R^y is independently selected from hydrogen, halo and C_{1-4} alkyl.

78. The compound of any of claims 1 to 3 or 10 to 68 or the compound for use as a medicament according to any of claims 4, 6 or 10 to 68 or the pharmaceutical composition of any of claims 7 or 9 to 68, wherein R^w and R^z are fluoro and each R^x and R^y is independently selected from hydrogen, halo and C_{1-4} alkyl.

79. The compound of any of claims 1 to 3 or 10 to 78 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 78 or the pharmaceutical composition of any of claims 7 to 78, wherein the substituents –A-B and –NH-D on the cyclopropyl moiety are in trans-configuration.

80. The compound of claim 1 or the compound for use as a medicament according to claim 4 or 6 or the pharmaceutical composition of claim 7 or 9, wherein said compound is selected from:

N1-((trans)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

(cis)-N1-((1S,2R)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

(trans)-N1-((1S,2R)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

(cis)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

(trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(thiazol-5-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

4-(((trans)-2-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)cyclopropyl)amino)cyclohexanol;

4-(((trans)-2-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)cyclopropyl)amino)cyclohexanecarboxamide;

N-(4-(((trans)-2-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)cyclopropyl)amino)cyclohexyl)acetamide;

N-(4-(((trans)-2-(6-(3-(trifluoromethyl)phenyl)pyridin-3-yl)cyclopropyl)amino)cyclohexyl)methanesulfonamide;

(R)-1-(4-(((trans)-2-phenylcyclopropyl)amino)cyclohexyl)pyrrolidin-3-amine;

N1-((trans)-2-(4'-chloro-[1,1'-biphenyl]-4-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(3'-chloro-[1,1'-biphenyl]-4-yl)cyclopropyl)cyclohexane-1,4-diamine;

4'-((trans)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-ol;

N-(4'-((trans)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)methanesulfonamide;

N1-((trans)-2-(4-((2-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(4-((3-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(4-((4-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-methyl-N4-((trans)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

N1-methyl-N4-((trans)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)-N4-methylcyclohexane-1,4-diamine;

N1-((trans)-2-phenylcyclopropyl)cyclobutane-1,3-diamine;

N1-((trans)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclopropyl)cyclobutane-1,3-diamine;

N1-((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)cyclobutane-1,3-diamine;

N1-((trans)-2-phenylcyclopropyl)-2,3-dihydro-1H-indene-1,3-diamine;

N1-((trans)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclopropyl)-2,3-dihydro-1H-indene-1,3-diamine;

N1-((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)-2,3-dihydro-1H-indene-1,3-diamine;

N1-((trans)-2-fluoro-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

N1-((1S,2S)-2-fluoro-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

N1-((1R,2R)-2-fluoro-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

1-methyl-N4-((*trans*)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

4-(aminomethyl)-N-((*trans*)-2-phenylcyclopropyl)cyclohexanamine;

N1-((*trans*)-2-phenylcyclopropyl)cyclohexane-1,3-diamine;

N1-((*cis*)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

Tert-butyl (4-(((*trans*)-2-phenylcyclopropyl)amino)cyclohexyl)carbamate;

1-ethyl-3-(4-(((*trans*)-2-phenylcyclopropyl)amino)cyclohexyl)urea;

4-morpholino-N-((*trans*)-2-phenylcyclopropyl)cyclohexanamine;

N1-((*trans*)-2-(4-bromophenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-(2-(o-tolyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-(2-(4-(trifluoromethyl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-(2-(4-methoxyphenyl)cyclopropyl)cyclohexane-1,4-diamine;

4-(2-((4-aminocyclohexyl)amino)cyclopropyl)phenol;

N1-(2-(2-fluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-(2-(3,4-difluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-(2-(naphthalen-2-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-(2-methyl-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

(R)-1-(4-(((*trans*)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclopropyl) amino)cyclohexyl)pyrrolidin-3-amine;

(*Cis*)-N1-((1S,2R)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclopropyl)cyclohexane-1,4-diamine;

(*Trans*)-N1-((1S,2R)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclo-propyl)cyclohexane-1,4-diamine;

(*Cis*)-N1-((1R,2S)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclo-propyl)cyclohexane-1,4-diamine;

(*Trans*)-N1-((1R,2S)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclo-propyl)cyclohexane-1,4-diamine;

N1-((*trans*)-2-(4-cyclopropylphenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((*trans*)-2-(4-(pyridin-3-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((*trans*)-2-(4-(1H-indazol-6-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((*trans*)-2-(4-(1H-pyrazol-5-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

3-(5-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)thiophen-2-yl)phenol;

3-(5-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)thiazol-2-yl)phenol;

3-(5-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)pyridin-2-yl)-5-methoxybenzonitrile;

5-(5-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)pyridin-2-yl)-2-methylphenol;

N-(4'-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)-6-methoxy-[1,1'-biphenyl]-3-yl)methanesulfonamide;

N-(3-(5-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)thiazol-2-yl)phenyl)-2-cyanobenzenesulfonamide ;

N-(4'-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)-2-cyanobenzenesulfonamide;

6-amino-N-(4'-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)pyridine-3-sulfonamide;

N-(4'-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)piperazine-1-sulfonamide;

N1-((*cis*)-2-fluoro-2-phenylcyclopropyl)cyclohexane-1,4-diamine;

N1-((*trans*)-2-(4-((3-(piperazin-1-yl)benzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((*trans*)-2-(4-(pyridin-3-ylmethoxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((*trans*)-2-(6-((3-methylbenzyl)amino)pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine;

3-((5-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)pyridin-2-yl) amino)benzonitrile;

N1-((trans)-2-(naphthalen-2-yl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(o-tolyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(4-methoxyphenyl)cyclopropyl)cyclohexane-1,4-diamine;

N1-((trans)-2-(2-fluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;
N1-((trans)-2-(3,4-difluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;
N1-((trans)-2-methyl-2-phenylcyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1S,2R*)-2-(pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine ;
(*trans*)-N1-((*1R,2S*)-2-(pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1R,2S*)-2-(pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1S,2R*)-2-(pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1S,2R*)-2-phenylcyclopropyl)cyclobutane-1,3-diamine ;
(*trans*)-N1-((*1R,2S*)-2-phenylcyclopropyl)cyclobutane-1,3-diamine;
(*cis*)-N1-((*1R,2S*)-2-phenylcyclopropyl)cyclobutane-1,3-diamine ;
(*trans*)-N1-((*1S,2R*)-2-phenylcyclopropyl)cyclobutane-1,3-diamine;
(*cis*)-N1-((*1S,2R*)-2-(3,4-difluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1R,2S*)-2-(3,4-difluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1R,2S*)-2-(3,4-difluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1S,2R*)-2-(3,4-difluorophenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1S,2R*)-2-(naphthalen-2-yl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1R,2S*)-2-(naphthalen-2-yl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1R,2S*)-2-(naphthalen-2-yl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1S,2R*)-2-(naphthalen-2-yl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1S,2R*)-2-(4-(1H-pyrazol-5-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1R,2S*)-2-(4-(1H-pyrazol-5-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1R,2S*)-2-(4-(1H-pyrazol-5-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1S,2R*)-2-(4-(1H-pyrazol-5-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine;
N-(4'-((*1R,2S*)-2-(((*cis*)-4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)piperazine-1-sulfonamide;
N-(4'-((*1S,2R*)-2-(((*trans*)-4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)piperazine-1-sulfonamide;
N-(4'-((*1S,2R*)-2-(((*cis*)-4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)piperazine-1-sulfonamide;
N-(4'-((*1R,2S*)-2-(((*trans*)-4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)piperazine-1-sulfonamide;
(*cis*)-N1-((*1S,2R*)-2-(4-((2-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1R,2S*)-2-(4-((2-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*cis*)-N1-((*1R,2S*)-2-(4-((2-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine;
(*trans*)-N1-((*1S,2R*)-2-(4-((2-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine; and
salts and solvates thereof.

81. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((trans)-2-

phenylcyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

82. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is (cis)-N1-((1S,2R)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, or a salt or solvate thereof.

83. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is (trans)-N1-((1S,2R)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, or a salt or solvate thereof.

84. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is (cis)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, or a salt or solvate thereof.

85. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, or a salt or solvate thereof.

86. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((trans)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

87. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is (*Cis*)-N1-((1R,2S)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclo-propyl)cyclohexane-1,4-diamine, or a salt or solvate thereof.

88. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is (*Trans*)-N1-((1R,2S)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)cyclo-propyl)cyclohexane-1,4-diamine, or a salt or solvate thereof.

89. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is 4-(aminomethyl)-N-((*trans*)-2-phenylcyclopropyl)cyclohexanamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

90. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((*trans*)-2-phenylcyclopropyl)cyclobutane-1,3-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

91. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((trans)-2-(pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

92. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-methyl-N4-((*trans*)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

93. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((*trans*)-2-(4-(1H-pyrazol-5-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

94. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N-(4'-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)piperazine-1-sulfonamide, an optically active stereoisomer thereof, or a salt or solvate thereof.

95. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((*trans*)-2-(4-((2-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

96. The compound of any of claims 1, 2, 10 to 81, 86 or 89 to 95 or the compound for use as a medicament according to any of claims 4 to 6, 10 to 81, 86 or 89 to 95 or the pharmaceutical composition of any of claims 7 to 81, 86 or 89 to 95, wherein said compound is an optically active stereoisomer.

97. The compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96 for use in the treatment or prevention of cancer.

98. The compound for use according to claim 97 or the pharmaceutical composition for use according to claim 97, wherein said cancer is chosen from breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, skin cancer, blood cancer, leukemia, lymphoma and myeloma.

99. The compound for use according to claim 97 or the pharmaceutical composition for use according to claim 97, wherein said cancer is blood cancer.

100. The compound for use according to claim 97 or the pharmaceutical composition for use according to claim 97, wherein said cancer is leukemia.

101. The compound for use according to claim 98 or 100 or the pharmaceutical composition for use according to claim 98 or 100, wherein said leukemia is chosen from acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and hairy cell leukemia.

102. The compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96 for use in the treatment or prevention of a neurological disease.

103. The compound for use according to claim 102 or the pharmaceutical composition for use according to claim 102, wherein said neurological disease is selected from depression, Alzheimer's disease, Huntington disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Dementia with Lewy Bodies, or Frontotemporal Dementia.

104. The compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96 for use in the treatment or prevention a viral infection.

105. The compound for use according to claim 104 or the pharmaceutical composition for use according to claim 104, wherein said viral infection is a herpesvirus infection.

106. The compound for use according to claim 105 or the pharmaceutical composition for use according to claim 105, wherein said herpesvirus infection is caused by and/or associated with a herpesvirus chosen from HSV-1, HSV-2 and Epstein-Barr virus.

107. The compound for use according to claim 104 or the pharmaceutical composition for use according to claim 104, wherein said viral infection is caused by and/or associated with HIV.

108. The compound for use according to claim 104 or the pharmaceutical composition for use according to claim 104, wherein said viral infection is caused by and/or associated with a *Hepadnavirus*.

109. The compound for use according to claim 108 or the pharmaceutical composition for use according to claim 108, wherein said *Hepadnavirus* is Hepatitis B virus.

110. The compound for use according to claim 104 or the pharmaceutical composition for use according to claim 104, wherein said viral infection is caused by and/or associated with a *Flavivirus*.

111. The compound for use according to claim 110 or the pharmaceutical composition for use according to claim 110, wherein said *Flavivirus* is chosen from Hepatitis C virus (HCV), yellow fever virus, West Nile virus, Dengue virus and Japanese encephalitis virus.

112. The compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96 for use in the treatment or prevention of viral reactivation after latency.

113. The compound for use according to claim 112 or the pharmaceutical composition for use according to claim 112, wherein the virus that is reactivating is a herpesvirus.

114. The compound for use according to claim 113 or the pharmaceutical composition for use according to claim 113, wherein said herpesvirus is chosen from HSV-1, HSV-2 and Epstein-Barr virus.

115. The compound for use according to claim 112 or the pharmaceutical composition for use according to claim 112, wherein the virus that is reactivating is HIV.

116. A method of treating or preventing cancer, the method comprising administering, to a subject in need of such treatment or prevention, a compound of formula I



I

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and –C_{1-4} alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and

each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol.

117. The method of claim 116, wherein said compound is a compound of formula Ia



Ia

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from –NR^7R^8, -NHOH, -NR^9COR^{10}, -$NR^9SO_2R^{10}$, -NR^9COOR^{10}, -$NR^9CONR^7R^8$, -$NR^9SO_2NR^7R^8$, -OH, –$CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkyene-

NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and –C_{1-4} alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and –$NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl; and

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol.

118. A method of treating or preventing a disease, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

119. A method of treating or preventing cancer, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

120. The method of any of claims 116, 117 or 119, wherein said cancer is chosen from breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, skin cancer, blood cancer, leukemia, lymphoma and myeloma.

121. The method of claim 120, wherein said cancer is blood cancer.

122. The method of claim 120, wherein said cancer is leukemia.

123. The method of claim 120 or 122, wherein said leukemia is chosen from acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and hairy cell leukemia.

124. A method of treating or preventing a neurological disease, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

125. The method of claim 124, wherein said neurological disease is selected from depression, Alzheimer's disease, Huntington disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Dementia with Lewy Bodies, or Frontotemporal Dementia.

126. A method of treating or preventing a viral infection, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

127. The method of claim 126, wherein said viral infection is a herpesvirus infection.

128. The method of claim 127, wherein said herpesvirus infection is caused by and/or associated with a herpesvirus chosen from HSV-1, HSV-2 and Epstein-Barr virus.

129. The method of claim 126, wherein said viral infection is caused by and/or associated with HIV.

130. The method of claim 126, wherein said viral infection is caused by and/or associated with a *Hepadnavirus*.

131. The method of claim 130, wherein said *Hepadnavirus* is Hepatitis B virus.

132. The method of claim 126, wherein said viral infection is caused by and/or associated with a *Flavivirus*.

133. The method of claim 132, wherein said *Flavivirus* is chosen from Hepatitis C virus (HCV), yellow fever virus, West Nile virus, Dengue virus and Japanese encephalitis virus.

134. A method for treating or preventing viral reactivation after latency, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

135. The method of claim 134, wherein the virus that is reactivating is a herpesvirus.

136. The method of claim 135, wherein said herpesvirus is chosen from HSV-1, HSV-2 and Epstein-Barr virus.

137. The method of claim 134, wherein the virus that is reactivating is HIV.

138. The method of any of claims 116 to 137, wherein said subject is a human.

139. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises reacting a compound of formula II



II

wherein A, B, R^w, R^x, R^y, and R^z have the meanings defined for the compound of formula I in claim 1, with a compound of formula III



III

wherein D has the meaning defined for the compound of formula I in claim 1, and wherein the group(s) R^3 on ring D are optionally protected with a protecting group,

in the presence of a reducing agent, followed by the removal of any protecting group that may be present.

140. The process of claim 139, wherein said reducing agent is a borohydride.

dated this 02 day of May 2014.

(Arindam Paul)
REG. No.: IN/PA-174
of De Penning & De Penning
(Agent For The Applicants)